Last reviewed · How we verify

Ivermectin 0.1% Metronidazole 1%

Universidad Nacional de Colombia · Phase 3 active Small molecule

Ivermectin 0.1% Metronidazole 1% is a Antiparasitic/Antimicrobial combination Small molecule drug developed by Universidad Nacional de Colombia. It is currently in Phase 3 development for Parasitic and anaerobic bacterial skin infections (investigational). Also known as: 22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b.

This combination product uses ivermectin to paralyze parasites and metronidazole to disrupt microbial DNA, targeting parasitic and anaerobic bacterial infections.

This combination product uses ivermectin to paralyze parasites and metronidazole to disrupt microbial DNA, targeting parasitic and anaerobic bacterial infections. Used for Parasitic and anaerobic bacterial skin infections (investigational).

At a glance

Generic nameIvermectin 0.1% Metronidazole 1%
Also known as22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b
SponsorUniversidad Nacional de Colombia
Drug classAntiparasitic/Antimicrobial combination
TargetGlutamate-gated chloride channels (ivermectin); DNA/anaerobic metabolism (metronidazole)
ModalitySmall molecule
Therapeutic areaInfectious Disease / Dermatology
PhasePhase 3

Mechanism of action

Ivermectin binds to glutamate-gated chloride channels in parasites, causing paralysis and death. Metronidazole is a nitroimidazole that generates reactive oxygen species and damages DNA in anaerobic organisms. Together, they provide broad-spectrum activity against parasites and anaerobic bacteria, likely for topical or systemic treatment of mixed infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ivermectin 0.1% Metronidazole 1%

What is Ivermectin 0.1% Metronidazole 1%?

Ivermectin 0.1% Metronidazole 1% is a Antiparasitic/Antimicrobial combination drug developed by Universidad Nacional de Colombia, indicated for Parasitic and anaerobic bacterial skin infections (investigational).

How does Ivermectin 0.1% Metronidazole 1% work?

This combination product uses ivermectin to paralyze parasites and metronidazole to disrupt microbial DNA, targeting parasitic and anaerobic bacterial infections.

What is Ivermectin 0.1% Metronidazole 1% used for?

Ivermectin 0.1% Metronidazole 1% is indicated for Parasitic and anaerobic bacterial skin infections (investigational).

Who makes Ivermectin 0.1% Metronidazole 1%?

Ivermectin 0.1% Metronidazole 1% is developed by Universidad Nacional de Colombia (see full Universidad Nacional de Colombia pipeline at /company/universidad-nacional-de-colombia).

Is Ivermectin 0.1% Metronidazole 1% also known as anything else?

Ivermectin 0.1% Metronidazole 1% is also known as 22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b.

What drug class is Ivermectin 0.1% Metronidazole 1% in?

Ivermectin 0.1% Metronidazole 1% belongs to the Antiparasitic/Antimicrobial combination class. See all Antiparasitic/Antimicrobial combination drugs at /class/antiparasitic-antimicrobial-combination.

What development phase is Ivermectin 0.1% Metronidazole 1% in?

Ivermectin 0.1% Metronidazole 1% is in Phase 3.

What are the side effects of Ivermectin 0.1% Metronidazole 1%?

Common side effects of Ivermectin 0.1% Metronidazole 1% include Skin irritation or burning, Pruritus, Erythema, Metallic taste (if systemic absorption).

What does Ivermectin 0.1% Metronidazole 1% target?

Ivermectin 0.1% Metronidazole 1% targets Glutamate-gated chloride channels (ivermectin); DNA/anaerobic metabolism (metronidazole) and is a Antiparasitic/Antimicrobial combination.

Related